EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway

Xiaoyu Yi, Chao Zhang, Baojie Liu, Guojun Gao, Yaqi Tang, Yongzheng Lu, Zhifang Pan, Guohui Wang, Weiguo Feng iD

Journal of Cellular and Molecular Medicine · 2023-02 · 27 (3) · 403-411

DOI: 10.1111/jcmm.17663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 10.01.2023. Verfasst von Xiaoyu Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Weifang Medical University, Weifang, China. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is one of the most common malignancies in men. Ribosomal protein L22‐like1 (RPL22L1), a component of the ribosomal 60 S subunit, is associated with cancer progression, but the role and potential mechanism of RPL22L1 in PCa remain unclear. The aim of this study was to investigate the role of RPL22L1 in PCa progression and the mechanisms involved. Bioinformatics and immunohistochemistry analysis showed that the expression of RPL22L1 was significantly higher in PCa tissues than in normal prostate tissues. The cell function analysis revealed that RPL22L1 significantly promoted the proliferation, migration and invasion of PCa cells. The data of xenograft tumour assay suggested that the low expression of RPL22L1 inhibited the growth and invasion of PCa cells in vivo. Mechanistically, the results of Western blot proved that RPL22L1 activated PI3K/Akt/mTOR pathway in PCa cells. Additionally, LY294002, an inhibitor of PI3K/Akt pathway, was used to block this pathway. The results showed that LY294002 remarkably abrogated the oncogenic effect of RPL22L1 on PCa cell proliferation and invasion. Taken together, our study demonstrated that RPL22L1 is a key gene in PCa progression and promotes PCa cell proliferation and invasion via PI3K/Akt/mTOR pathway, thus potentially providing a new target for PCa therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesCell Line, TumorTOR Serine-Threonine KinasesCell ProliferationRibosomal ProteinsCell Movement

Stichwörter der Autor:innen

PI3K/Akt/mTORRPL22L1invasionproliferationprostate cancer

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesRibosomal ProteinsMTOR protein, human

Autor:innen und Institutionen

  • School of Life Science and Technology, Weifang Medical University, Weifang, China.
  • Department of Urology Surgery, Shandong Cancer Hospital and Institute, Jinan, China.
  • Department of Urology Surgery, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Department of Urology Surgery, Affiliated Hospital of Weifang Medical University, Weifang, China.

ORCID-Profile: Weiguo Feng

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Yi, X., Zhang, C., Liu, B., Gao, G., Tang, Y., Lu, Y., Pan, Z., Wang, G., & Feng, W. (2023). Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway. Journal of Cellular and Molecular Medicine, 27(3), 403-411. https://doi.org/10.1111/jcmm.17663

Vancouver

Yi X, Zhang C, Liu B, Gao G, Tang Y, Lu Y, et al. Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway. Journal of Cellular and Molecular Medicine. 2023;27(3):403-411. doi:10.1111/jcmm.17663

BibTeX
@article{Yi2023,
  author = {Yi, Xiaoyu and Zhang, Chao and Liu, Baojie and Gao, Guojun and Tang, Yaqi and Lu, Yongzheng and Pan, Zhifang and Wang, Guohui and Feng, Weiguo},
  title = {Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  volume = {27},
  number = {3},
  pages = {403--411},
  doi = {10.1111/jcmm.17663}
}
Kostenlos starten →